Chromosome 19 rearrangements in ovarian carcinomas: Zinc finger genes are particularly targeted

Genes Chromosomes and Cancer

Volumn 53, Issue 7, 2014, Pages 558-567

  Smebye, Marianne L ^a,b   Sveen, Anita ^a,b   Haugom, Lisbeth ^a,b   Davidson, Ben ^a,c   Tropé, Claes G ^a   Lothe, Ragnhild A ^a,b   Heim, Sverre ^a,b,c   Skotheim, Rolf I ^a,b   Micci, Francesca ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ZINC FINGER PROTEIN;

ARTICLE; CARCINOGENESIS; CHROMOSOME 19; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE MAPPING; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; KARYOTYPE; OVARY CARCINOMA; PRIORITY JOURNAL; UPREGULATION; ZINC FINGER MOTIF; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; GENETICS; METABOLISM; OVARY TUMOR;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 19; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; ZINC FINGERS;

EID: 84899901266     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22166     Document Type: Article

References (36)

1. Bast RC, Jr., Hennessy B, Mills GB. 2009. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 9:415-428.
2. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 2010. The landscape of somatic copy number alteration across human cancers. Nature 463:899-905.
3. Bowtell DDL. 2010. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803-808.
4. Brekke HR, Ribeiro FR, Kolberg M, Agesen TH, Lind GE, Eknaes M, Hall KS, Bjerkehagen B, van den Berg E, Teixeira MR, Mandahl N, Smeland S, Mertens F, Skotheim RI, Lothe RA. 2010. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol 28:1573-1582.
5. Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
6. Corsinotti A, Kapopoulou A, Gubelmann C, Imbeault M, Santoni de Sio FR, Rowe HM, Mouscaz Y, Deplancke B, Trono D. 2013. Global and stage specific patterns of Kr++ppel-associated-box zinc finger protein gene expression in murine early embryonic cells. PLoS One 8:e56721.
7. Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM. 2012. ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PLoS One 7:e46317.
8. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. 2008. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112:1489-1502.
9. Ghaemmaghami S, Huh WK, Bower K, Howson RW, Belle A, Dephoure N, O'Shea EK, Weissman JS. 2003. Global analysis of protein expression in yeast. Nature 425:737-741.
10. Gorringe KL, Campbell IG. 2009. Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 3:157-164.
11. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DD. 2010. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 5.
12. Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U, Goodstein D, Couronne O, Tran-Gyamfi M, Aerts A, Altherr M, Ashworth L, Bajorek E, Black S, Branscomb E, Caenepeel S, Carrano A, Caoile C, Chan YM, Christensen M, Cleland CA, Copeland A, Dalin E, Dehal P, Denys M, Detter JC, Escobar J, Flowers D, Fotopulos D, Garcia C, Georgescu AM, Glavina T, Gomez M, Gonzales E, Groza M, Hammon N, Hawkins T, Haydu L, Ho I, Huang W, Israni S, Jett J, Kadner K, Kimball H, Kobayashi A, Larionov V, Leem SH, Lopez F, Lou Y, Lowry S, Malfatti S, Martinez D, McCready P, Medina C, Morgan J, Nelson K, Nolan M, Ovcharenko I, Pitluck S, Pollard M, Popkie AP, Predki P, Quan G, Ramirez L, Rash S, Retterer J, Rodriguez A, Rogers S, Salamov A, Salazar A, She X, Smith D, Slezak T, Solovyev V, Thayer N, Tice H, Tsai M, Ustaszewska A, Vo N, Wagner M, Wheeler J, Wu K, Xie G, Yang J, Dubchak I, Furey TS, Dejong P, Dickson M, Gordon D, Eichler EE, Pennacchio LA, Richardson P, Stubbs L, Rokhsar DS, Myers RM, Rubin EM, Lucas SM. 2004. The DNA sequence and biology of human chromosome 19. Nature 428:529-535.
13. Huntley S, Baggott DM, Hamilton AT, Tran-Gyamfi M, Yang S, Kim J, Gordon L, Branscomb E, Stubbs L. 2006. A comprehensive catalog of human KRAB-associated zinc finger genes: insights into the evolutionary history of a large family of transcriptional repressors. Genome Res 16:669-677.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA: A Cancer J Clin 61:69-90.
16. Jenkins RB, Bartelt D, Jr., Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, Hartmann L. 1993. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71:76-86.
17. Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, Abeler VM, Silins I, Lothe RA, Trope CG, Arnold N, Heim S. 2009. Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer 48:184-193.
18. Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AM, Abeler VM, Trope CG, Arnold N, Lothe RA, Heim S. 2010. Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes. Genes Chromosomes Cancer 49:1046-1053.
19. Mitelman F. 2000. Recurrent chromosome aberrations in cancer. Mutat Res 462:247-253.
20. Mitelman F, Johansson B, Mertens F. 2013. Mitelman database of chromosome aberrations and gene fusions in cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed June 19, 2013.
21. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih I, Wang TL. 2007. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120:2613-2617.
22. O'Geen H, Squazzo SL, Iyengar S, Blahnik K, Rinn JL, Chang HY, Green R, Farnham PJ. 2007. Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs. PLoS Genet 3:e89.
23. Pejovic T, Heim S, Mandahl N, Elmfors B, Floderus UM, Furgyik S, Helm G, Willen H, Mitelman F. 1989. Consistent occurrence of a 19p+ marker chromosome and loss of 11p material in ovarian seropapillary cystadenocarcinomas. Genes Chromosomes Cancer 1:167-171.
24. Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, Floderus UM, Furgyik S, Helm G, Himmelmann A, Willen H. 1992. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 4:58-68.
25. Prensner JR, Chinnaiyan AM. 2009. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev 19:82-91.
26. Rink L, Ochs MF, Zhou Y, von MM, Godwin AK. 2013. ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One 8:e54477.
27. Shih I, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL. 2011. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol 24:638-645.
28. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavar+® S, Deloukas P, Hurles ME, Dermitzakis ET. 2007. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315:848-853.
29. Sun G, Zhou J, Yin A, Ding Y, Zhong M. 2008. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Int J Oncol 32:1065-1071.
30. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L, Davis JR, Trent J, Alberts DS. 1999. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 25:290-300.
31. Urrutia R. 2003. KRAB-containing zinc-finger repressor proteins. Genome Biol 4:231.
32. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. 2009. A census of human transcription factors: function, expression and evolution. Nat Rev Genet 10:252-263.
33. Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R. 2011. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One 6:e28503.
34. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. 2011. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30:1329-1440.
35. Yu J, Liang QY, Wang J, Cheng Y, Wang S, Poon TCW, Go MYY, Tao Q, Chang Z, Sung JJY. 2013. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene 32:307-317.
36. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. 2004. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 64:3060-3071.